(5-Ethyl-1H-pyrazol-3-yl)methanol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (5-Ethyl-1H-pyrazol-3-yl)methanol
• 英文别名: (3-ethyl-1H-pyrazol-5-yl)methanol
• 化学式: C₆H₁₀N₂O
• 分子量: 126.16
• InChiKey: BPJLSYGANNQDOB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  48.9
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• [EN] PYRAZOLES<br/>[FR] PYRAZOLES
  申请人：JANSSEN PHARMACEUTICALS INC

  公开号：WO2016025918A1

  公开（公告）日：2016-02-18

  The invention relates to pyrazole derivatives which are NMDA NR2B receptor inhibitors, useful in treating central nervous system diseases.

  这项发明涉及吡唑衍生物，它们是NMDA NR2B受体抑制剂，可用于治疗中枢神经系统疾病。
• Spiro compounds for treatment of inflammatory disorders
  申请人：Weingarten M. David

  公开号：US20080280974A1

  公开（公告）日：2008-11-13

  Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of an inflammatory condition, in particular asthma. The compounds are of the general Formula I, or a pharmaceutically acceptable salt, ester, prodrug or derivative thereof: wherein Y, Z and R 1 -R 12 are defined herein.

  提供了化合物、药物组合物以及治疗或预防炎症性疾病，特别是哮喘的方法。这些化合物属于一般的I式，或其药用可接受的盐、酯、前药或衍生物：其中Y、Z和R1-R12在此处定义。
• Benzimidazole derivatives and their use as kdr kinase protein inhibitors
  申请人：Babin Didier

  公开号：US20080125418A1

  公开（公告）日：2008-05-29

  The invention discloses and claims benzimidazole compounds of formula (I): wherein X is C—R2; Y is C—R2 or C—R3; W and Z are each C—R3; R1 is an optionally substituted aryl, heteroaryl or a saturated 5- or 6-membered monocyclic heterocyclic radical or a bicyclic heterocyclic radical; and A5 is H or alkyl; or a stereoisomer, a racemate, an enantiomer or a diastereoisomer of said compound of formula (I) or a pharmaceutically acceptable salt thereof; the use of compounds of formula (I) for the treatment of a disorder of proliferation of blood vessels, uncontrolled angiogenesis, a fibrotic disorder, a disorder of proliferation of mesangial cells, a metabolic disorder, allergy, asthma, thrombosis, a disease of the nervous system, retinopathy, psoriasis, rheumatoid arthritis, diabetes, muscle degeneration, solid tumors and cancers, pharmaceutical compositions comprising a compound of formula (I) and one or more pharmaceutically acceptable adjuvants or diluents and pharmaceutical compositions comprising a compound of formula (I) and one or more. antimitotic agents.

  本发明揭示和声明了式（I）的苯并咪唑化合物：其中X是C-R2; Y是C-R2或C-R3; W和Z均为C-R3; R1是可选择取代的芳基，杂芳基或饱和的5-或6-成员单环杂环基或双环杂环基; A5是H或烷基; 或者是式（I）的立体异构体，外消旋体，对映异构体或二对映异构体或其药学上可接受的盐; 本发明还涉及使用式（I）的化合物治疗血管增殖障碍，无控制的血管生成，纤维化障碍，系膜细胞增殖障碍，代谢障碍，过敏，哮喘，血栓形成，神经系统疾病，视网膜病变，牛皮癣，类风湿性关节炎，糖尿病，肌肉退化，实体瘤和癌症的药物组合物，包括式（I）的化合物和一个或多个药学上可接受的辅料或稀释剂以及包括式（I）的化合物和一个或多个抗有丝分裂剂的药物组合物。
• PYRAZOLES
  申请人：Janssen Pharmaceuticals, Inc.

  公开号：EP3180315B1

  公开（公告）日：2020-03-18
• US8288425B2
  申请人：——

  公开号：US8288425B2

  公开（公告）日：2012-10-16

表征谱图